PRAMOMOLECULAR
PRAMOMOLECULAR is dedicated to developing innovative gene silencing therapies using self-delivering siRNAs. Their mission is to provide effective and well-tolerated therapeutics for serious diseases, including cancer and heart failure, by leveraging proprietary platform technology for nucleic acid-based drugs. They aim to address currently incurable diseases and collaborate with other developers through co-development and licensing of their delivery technology.
Industries
Nr. of Employees
small (1-50)
PRAMOMOLECULAR
Berlin, Berlin, Germany, Europe
Products
Self-delivering siRNA drug candidates (pipeline)
A pipeline of siRNA-based therapeutic candidates formulated with lipid-conjugated delivery molecules designed to downregulate mutated or overexpressed proteins; intended indications include KRAS-dependent cancers and heart failure.
Self-delivering siRNA drug candidates (pipeline)
A pipeline of siRNA-based therapeutic candidates formulated with lipid-conjugated delivery molecules designed to downregulate mutated or overexpressed proteins; intended indications include KRAS-dependent cancers and heart failure.
Services
Co-development and licensing of nucleic acid delivery technology
Partnership-based co-development and licensing of delivery chemistries and formulations for nucleic acid-based drugs.
Preclinical in vivo efficacy studies
Design and execution of in vivo proof-of-concept studies in mouse PDX models to evaluate efficacy of nucleic acid therapeutic candidates against oncogenic targets.
Co-development and licensing of nucleic acid delivery technology
Partnership-based co-development and licensing of delivery chemistries and formulations for nucleic acid-based drugs.
Preclinical in vivo efficacy studies
Design and execution of in vivo proof-of-concept studies in mouse PDX models to evaluate efficacy of nucleic acid therapeutic candidates against oncogenic targets.
Expertise Areas
- siRNA therapeutics and gene silencing
- Nucleic acid delivery chemistry and formulation
- Preclinical oncology models and in vivo efficacy studies
- Tissue-targeted delivery to lung, heart and pancreas
Key Technologies
- siRNA-mediated gene silencing
- Lipid-conjugated delivery molecules for nucleic acids
- Patient-derived xenograft (PDX) mouse models
- Systemic, intraperitoneal and local administration of therapeutics